Department of Internal Medicine II, University-Hospital Campus Grosshadern, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System (GEPNET-KUM), Ludwig-Maximilians-University of Munich, Munich 81377, Germany.
Gut. 2011 Jul;60(7):1009-21. doi: 10.1136/gut.2009.204453. Epub 2011 Mar 4.
Multimodal treatment options for advanced gastroenteropancreatic neuroendocrine tumours (NET) of jejunum/ileum and of pancreatic origin are reviewed. Current topics being discussed are: European Neuroendocrine Tumour Society 2006/7, American Joint Cancer Committee/Union Internationale Contre le Cancer 2009 and WHO 2010 recommendations for grading and staging of NET; surgery of the primary tumour in distant metastasised disease; surgery of metastatic liver disease and impact on survival; somatostatin analogues for symptom control and for tumour control; selective internal radiation therapy with 90Y-microspheres as novel local ablative therapy in liver metastases; peptide receptor radionuclide therapy; novel chemotherapy regimens (eg, temozolomide) and novel targeted therapies (eg, sunitinib and everolimus).
探讨了用于治疗空肠/回肠和胰腺来源的晚期胃肠胰神经内分泌肿瘤（NET）的多种治疗选择。目前正在讨论的议题包括：欧洲神经内分泌肿瘤学会 2006/07 年、美国联合癌症委员会/国际抗癌联盟 2009 年和世界卫生组织 2010 年关于 NET 分级和分期的建议；远处转移疾病中原发肿瘤的手术治疗；转移性肝疾病的手术治疗及其对生存率的影响；生长抑素类似物用于症状控制和肿瘤控制；90Y 微球选择性内放射治疗作为肝转移的新型局部消融治疗；肽受体放射性核素治疗；新型化疗方案（例如替莫唑胺）和新型靶向治疗（例如舒尼替尼和依维莫司）。
Zotero 插件